Life Sciences and Health Care

Analysis

2022 Global Health Care Outlook

Are we finally seeing the long-promised transformation?

The global health care sector continues to rise up to the new challenges presented by the ongoing pandemic, which continues to dominate health care systems’ attention and resources.

Article

Will Computer Software Assurance (CSA) improve product quality and patient safety?

While technology and computerised systems have advanced greatly in that time, the life sciences industry has been slow to amend Computer System Validation principles in in line with advancements. 

Perspectives

Securing Trust in the Global COVID-19 Supply Chain

From development and delivery to acceptance and administration

COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products. Are organizations ready to take on the challenge?

Perspectives

Measuring the return from pharmaceutical innovation 2021

Since 2010, we have been tracking the returns on R&D investment that the largest biopharma companies might expect to achieve from their late-stage pipelines. This year’s analysis shows a large improvement in the average internal rate of return on pharmaceutical innovation for our combined cohort. 

Article

Seeds of Change

Measuring the return of pharmaceutical innovation 2020

Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and identifies lessons that can help change the R&D paradigm towards a future with higher returns.

Article

As M&A activity and divestitures continue, life sciences companies shouldn’t overlook product transfers

   Imagine a $50 billion life sciences acquisition where company executives don’t properly plan for the transfer of some products. The potential result: Supply disruptions for patients and millions of dollars in unplanned inventory write-offs.

Article

Is the new EU medical device legislation worth the wait?

Understanding the new legislation

Article

The future of biopharma innovation

Biopharma’s future will be focused on developing therapies for the multiple diseases that still lack treatments and creating more precise treatment regimens that target smaller populations or individual patients. Developing these treatments brings new challenges.

Article

A decade of shrinking returns might be prompting pharma to adopt new business models

New partnerships were announced, and sessions highlighted new vaccines, cutting-edge immune-inflammation drugs, and advances in cell and gene therapies. But there was a palpable feeling of caution in the air.

Article

Medical device regulatory changes affect the bottom line

Planning for compliance with regulatory changes

Analysis

Top 10 health care innovations

More value, better outcomes, for less

Article

Unravelling complexity

The challenge of compliance in the life sciences supply chain